In the Boardroom - Pharmaceutical

Filter

Current filters:

Pharmaceutical

Popular Filters

120 to 144 of 6855 results

US FTC releases 2013 highlights, including action against Actavis and Mylan

US FTC releases 2013 highlights, including action against Actavis and Mylan

01-04-2014

The US Federal Trade Commission chairwoman Edith Ramirez has released the agency’s 2013 Annual Highlights,…

ActavisMylan LaboratoriesPharmaceuticalRegulationUSA

Otsuka acquires certain Dacogen and E7727 rights from Eisai

01-04-2014

Otsuka Pharmaceutical has reached an agreement with the US subsidiary of fellow Japanese drugmaker Eisai…

DacogenE7727EisaiLicensingOncologyOtsukaPharmaceutical

Lilly's Alimta patent upheld through 2022

Lilly's Alimta patent upheld through 2022

01-04-2014

US pharma major Eli Lilly says that the US District Court for the Southern District of Indiana has ruled…

AlimtaEli LillyLegalNorth AmericaOncologyPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

Price cuts mean PBS can afford new medicines, says Medicines Australia

Price cuts mean PBS can afford new medicines, says Medicines Australia

01-04-2014

As of today in Australia, price cuts come into effect for 121 medicines, and trade group Medicines Australia…

Asia-PacificAustraliaHealthcarePharmaceuticalPricing

Johnson & Johnson accepts $4 billion offer for Ortho-Clinical Diagnostics

Johnson & Johnson accepts $4 billion offer for Ortho-Clinical Diagnostics

01-04-2014

US health care giant Johnson & Johnson revealed yesterday that it has accepted the binding offer from…

Johnson & JohnsonMergers & AcquisitionsPharmaceutical

Lundbeck to enter a partnership with Lieber Institute

Lundbeck to enter a partnership with Lieber Institute

01-04-2014

Danish CNS specialist Lundbeck, together with a number of other companies, is now entering into a collaboration…

LundbeckNeurologicalPharmaceuticalResearch

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

01-04-2014

German drug major Bayer presented new analyses from the pivotal ROCKET AF and EINSTEIN clinical trials…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

US Supreme Court agrees to hear Teva’s Copaxone patent appeal

US Supreme Court agrees to hear Teva’s Copaxone patent appeal

01-04-2014

Israel’s Teva Pharmaceutical Industries, the world largest generic drugmaker, says that the US Supreme…

CopaxoneLegalNeurologicalNorth AmericaPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

Bayer’s Adempas gains EU clearance for two forms of PAH

Bayer’s Adempas gains EU clearance for two forms of PAH

31-03-2014

Following a previous positive opinion from the European Medicines Agency’s advisory committee, the…

AdempasBayerEuropePharmaceuticalRegulationRespiratory and Pulmonary

Novartis halts Ph III LCZ696 trial on strong results

Novartis halts Ph III LCZ696 trial on strong results

31-03-2014

Swiss drug major Novartis says that the Data Monitoring Committee (DMC) unanimously recommended early…

Cardio-vascularLCZ696NovartisPharmaceuticalResearch

Jazz Pharma and Gentium debut Defitelio in Europe

31-03-2014

Ireland-headquartered Jazz Pharmaceuticals and its Italian subsidiary Gentium have initiated the European…

AustriaDefitelioEuropeGentiumGermanyJazz PharmaceuticalsMarkets & MarketingPharmaceuticalRare diseases

Bayer Healthcare to invest 100 million euros to expand capacity in China

Bayer Healthcare to invest 100 million euros to expand capacity in China

31-03-2014

The HealthCare division of Germany’s Bayer will invest around 100 million euros ($137.5 million) to…

Asia-PacificBayerChinaFinancialPharmaceuticalProduction

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

31-03-2014

UK pharma major GlaxoSmithKline has withdrawn its application to the European Medicines Agency for a…

GlaxoSmithKlineOncologyPharmaceuticalRegulationUKVotrientWomen's Health

Skyepharma posts 25% revenue growth for 2013

31-03-2014

UK-based Skyepharma, an oral and inhalation drug delivery company, today released financial results for…

FinancialPharmaceuticalSkyepharma

Clinigen gains rights to SpePharm’s Savene

Clinigen gains rights to SpePharm’s Savene

31-03-2014

The UK’s specialty pharma firm Clinigen Group says it has acquired rights to Savene (dexrazoxane) from…

Clinigen GroupGlobalLicensingNorgineOncologyPharmaceuticalSaveneSpePharma

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

31-03-2014

Hong Kong-listed Lansen Pharmaceutical has acquired the pharmaceutical product, marketed and sold in…

Asia-PacificChinaDermatologicalsLansen PharmaceuticalMergers & AcquisitionsNovartisPharmaceuticalSicorten

Sanofi appoints Dr Anne Beal as chief patient officer

Sanofi appoints Dr Anne Beal as chief patient officer

31-03-2014

French drug major Sanofi has announced the appointment of Anne Beal to the newly created position of…

BiotechnologyBoardroomFrancePharmaceuticalSanofiUSA

aTyr Pharma appoints David Weiner as Chief Medical Officer

aTyr Pharma appoints David Weiner as Chief Medical Officer

31-03-2014

aTyr Pharma, a rare disease biotherapeutics enterprise, has announced the appointment of David Weiner…

aTyrBiotechnologyBoardroomUSA

ACC 2014: GSK’s darapladib disappoints in Ph III trial

ACC 2014: GSK’s darapladib disappoints in Ph III trial

31-03-2014

UK pharma major GlaxoSmithKline (LSE: GSK) presented disappointing data from its pivotal Phase III STABILITY…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearchUKUSA

AstraZeneca and MRC to create new discovery center in Cambridge

AstraZeneca and MRC to create new discovery center in Cambridge

31-03-2014

Anglo-Swedish drug major AstraZeneca and the UK Medical Research Council (MRC) have entered into a collaboration…

AstraZenecaNorthern EuropePharmaceuticalResearchUK

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

29-03-2014

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

Philippine government increasing financial support for health care spending

28-03-2014

The size of the Philippine pharmaceutical market, now worth around $3.2 billion, is expected to expand…

Asia-PacificFinancialGenericsMarkets & MarketingPharmaceutical

120 to 144 of 6855 results

Back to top